COVID-19 Death and BCG Vaccination Programs Worldwide
Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vacc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2021-01-01
|
| Series: | Tuberculosis and Respiratory Diseases |
| Subjects: | |
| Online Access: | http://www.e-trd.org/upload/pdf/trd-2020-0063.pdf |
| _version_ | 1818928756224425984 |
|---|---|
| author | Feras J. Jirjees Yahya H. Dallal Bashi Hala J. Al-Obaidi |
| author_facet | Feras J. Jirjees Yahya H. Dallal Bashi Hala J. Al-Obaidi |
| author_sort | Feras J. Jirjees |
| collection | DOAJ |
| description | Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases. |
| first_indexed | 2024-12-20T03:33:58Z |
| format | Article |
| id | doaj.art-9d08055751dd4a3db8206b7ba7798c93 |
| institution | Directory Open Access Journal |
| issn | 1738-3536 2005-6184 |
| language | English |
| last_indexed | 2024-12-20T03:33:58Z |
| publishDate | 2021-01-01 |
| publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
| record_format | Article |
| series | Tuberculosis and Respiratory Diseases |
| spelling | doaj.art-9d08055751dd4a3db8206b7ba7798c932022-12-21T19:54:56ZengThe Korean Academy of Tuberculosis and Respiratory DiseasesTuberculosis and Respiratory Diseases1738-35362005-61842021-01-01841132110.4046/trd.2020.00633270COVID-19 Death and BCG Vaccination Programs WorldwideFeras J. Jirjees0Yahya H. Dallal Bashi1Hala J. Al-Obaidi2 College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates School of Pharmacy, Queen’s University Belfast, Belfast, UK School of Pharmacy, Queen’s University Belfast, Belfast, UKSeveral clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases.http://www.e-trd.org/upload/pdf/trd-2020-0063.pdfcovid-19 pandemicbcg vaccinecovid-19 death casescoronaviruscovid-19 mortality |
| spellingShingle | Feras J. Jirjees Yahya H. Dallal Bashi Hala J. Al-Obaidi COVID-19 Death and BCG Vaccination Programs Worldwide Tuberculosis and Respiratory Diseases covid-19 pandemic bcg vaccine covid-19 death cases coronavirus covid-19 mortality |
| title | COVID-19 Death and BCG Vaccination Programs Worldwide |
| title_full | COVID-19 Death and BCG Vaccination Programs Worldwide |
| title_fullStr | COVID-19 Death and BCG Vaccination Programs Worldwide |
| title_full_unstemmed | COVID-19 Death and BCG Vaccination Programs Worldwide |
| title_short | COVID-19 Death and BCG Vaccination Programs Worldwide |
| title_sort | covid 19 death and bcg vaccination programs worldwide |
| topic | covid-19 pandemic bcg vaccine covid-19 death cases coronavirus covid-19 mortality |
| url | http://www.e-trd.org/upload/pdf/trd-2020-0063.pdf |
| work_keys_str_mv | AT ferasjjirjees covid19deathandbcgvaccinationprogramsworldwide AT yahyahdallalbashi covid19deathandbcgvaccinationprogramsworldwide AT halajalobaidi covid19deathandbcgvaccinationprogramsworldwide |